---
title: "HK Midday: HSI Up 0.6%, Chinese Banks Hit Record Highs, New World Plunges 40%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305622649.md"
description: "HSI rebounds over 130 pts; ICBC and CCB hit record highs intraday. New World Development resumes trading and crashes nearly 40%; Akeso slumps over 22%."
datetime: "2026-11-16T06:19:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305622649.md)
  - [en](https://longbridge.com/en/news/305622649.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305622649.md)
generator: "portal-rs"
---

# HK Midday: HSI Up 0.6%, Chinese Banks Hit Record Highs, New World Plunges 40%

## Index Overview

On November 16, Hong Kong's three major indices rebounded in intraday trading, with the Hang Seng Index at one point surging over 250 points toward the 23,900 level. As of press time, the HSI stood at **23,774.17**, up **0.58%** or 136.57 points; the HSCEI was at **7,985.42**, up **0.60%**; and the Hang Seng Tech Index was at **3,812.60**, edging down **0.02%**. Total market turnover was approximately **HK$123.5 billion**.

By sector, large-cap tech names were mixed, with Tencent and Alibaba ticking higher while Lenovo Group slid over 6%. Chinese banks rallied across the board, with ICBC and CCB both hitting record highs intraday. New World Development resumed trading after a deeply discounted rights issue and at one point plunged 47%. Biopharma stocks broadly declined, with Akeso tumbling over 22%.

## New World Development Resumes Trading, Crashes Nearly 40% on Rights Issue Priced at Over 60% Discount

New World Development (00017.HK) plunged after resuming trading today, hitting an intraday low of **HK$2.57**, at one point down as much as **47%**. As of press time, the stock traded at **HK$2.935**, down **39.84%**, with turnover exceeding **HK$699 million**.

The sell-off follows the company's announcement of a 2-for-1 rights issue at **HK$1.68** per share, a steep discount of over **65%** to the pre-suspension closing price of **HK$4.87**, aiming to raise approximately **HK$6.6 billion** for debt repayment and general working capital. Market concerns that the company's debt pressures remain unresolved triggered heavy selling upon the stock's trading resumption.

## Chinese Banks Rally Broadly, ICBC and CCB Both Hit Record Highs

As of press time, China Construction Bank (00939.HK) rose **1.71%** to **HK$10.68**; Industrial and Commercial Bank of China (01398.HK) gained **1.58%** to **HK$8.055**; Bank of China (03988.HK) added **1.43%** to **HK$6.37**; and Agricultural Bank of China (01288.HK) edged up **0.66%** to **HK$6.915**. ICBC and CCB both refreshed their all-time highs intraday.

Bank stocks have continued to attract capital, with high-dividend strategies gaining appeal amid a choppy market. While China's October economic data fell short of expectations, the market still holds expectations for year-end easing measures such as RRR cuts, and the banking sector, as an interest-rate-sensitive asset class, has been among the first to benefit. In addition, ICBC, CCB, ABC and BOC have all delivered substantial year-to-date gains, with solid fundamentals coupled with dividend expectations making them a primary destination for fund inflows.

## Biopharma Stocks Broadly Lower, Akeso Plunges Over 22%

As of press time, Akeso (09926.HK) tumbled **22.84%** to **HK$63.45**, having touched an intraday low of **HK$56.10**, with turnover exceeding **HK$3.7 billion**. BrainAurora-B (06681.HK) fell **7.30%** to **HK$1.27**; LifeTech Scientific (01302.HK) dropped **5.83%** to **HK$1.455**.

The sell-off was triggered by news that Akeso's core product, ivonescimab, has received a Complete Response Letter (CRL) from the FDA regarding its US marketing application, meaning its US commercialisation timeline will be delayed. Jefferies issued a report noting that the CRL is primarily related to manufacturing processes rather than drug efficacy or safety concerns, maintaining a Buy rating and a target price of **HK$226**, and arguing that the HARMONi-3 trial's failure to achieve statistical significance on OS was mainly due to insufficient follow-up time. Nevertheless, the market reacted sharply to the news, dragging the broader sector lower.

## Semiconductor and Tech Hardware Stocks Weaken

As of press time, Lenovo Group (00992.HK) dropped **6.07%** to **HK$16.51**; SMIC (00981.HK) fell **4.25%** to **HK$46.42**; Hua Hong Semiconductor (01347.HK) declined **4.15%** to **HK$69.30**; and Kingsoft Cloud (03896.HK) lost **3.72%** to **HK$3.88**. Kuaishou Technology (01024.HK) slipped **2.31%** to **HK$25.32**.

Overnight, South Korea's Samsung Electronics and SK Hynix both weakened, with SK Hynix at one point falling over **5%**, weighing on sentiment across the Asia-Pacific semiconductor sector. In addition, A-share optical module leader Zhongji Innolight extended its decline, and the broader AI hardware segment was soft, pulling Hong Kong semiconductor and hardware stocks lower in tandem.

## Other Sector Roundup

Oil stocks edged higher, with Sinopec (00386.HK) up **1.16%** and CNOOC (00883.HK) up **0.53%**. Chinese property stocks were mixed: China SCE Group (01966.HK) surged **26.92%** to **HK$0.033**, while Country Garden (02007.HK) fell **4.65%** and Sunac China (01918.HK) dropped **2.70%**. Gold and resources stocks were soft, with Zijin Mining Group (02899.HK) down **3.35%** and MMG (01208.HK) down **6.47%**. China Ruyi Holdings (00136.HK) tumbled **9.97%** to **HK$1.315**.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [01398.HK](https://longbridge.com/en/quote/01398.HK.md)
- [03988.HK](https://longbridge.com/en/quote/03988.HK.md)
- [01347.HK](https://longbridge.com/en/quote/01347.HK.md)
- [09988.HK](https://longbridge.com/en/quote/09988.HK.md)
- [01810.HK](https://longbridge.com/en/quote/01810.HK.md)

## Related News & Research

- [Akeso Announces Trustee Purchase of 200,000 Shares](https://longbridge.com/en/news/305977146.md)
- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [Akeso Proposes Additional On-Market Share Purchases](https://longbridge.com/en/news/305840563.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**